|
J&J Submits Supplemental Zytiga Apps as Some Experts Question Early Trial Stoppage
Johnson & Johnson (J&J) has submitted supplemental marketing applications to the FDA and European Medicines Agency (EMA) for its prostate cancer treatment Zytiga for use following failed androgen deprivation therapy but before chemotherapy.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives